ZNF407

Summary

ZNF407 (zinc finger protein 407, HGNC:19904) is a protein-coding gene on chromosome 18q23, encoding Zinc finger protein 407 (Q9C0G0). May be involved in transcriptional regulation. It is a selective cancer dependency (DepMap: 83.7% of cell lines).

This gene encodes a zinc finger protein whose exact function is not known. It may be involved in transcriptional regulation. Several alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 55628 — RefSeq curated summary.

At a glance

• Gene–disease (curated): short stature, impaired intellectual development, microcephaly, hypotonia, and ocular anomalies (Strong, GenCC) — +3 more curated relationships
• GWAS associations: 2
• Clinical variants (ClinVar): 468 total — 1 pathogenic
• Phenotypes (HPO): 27
• Cancer dependency (DepMap): dependent in 83.7% of screened cell lines
• Dosage sensitivity (ClinGen): haploinsufficiency no evidence, triplosensitivity no evidence
• MANE Select transcript: NM_017757

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19904
Approved symbol	ZNF407
Name	zinc finger protein 407
Location	18q23
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20307, FLJ13839, KIAA1703
Ensembl gene	ENSG00000215421
Ensembl biotype	protein_coding
OMIM	615894
Entrez	55628

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000299687, ENST00000309902, ENST00000577538, ENST00000579200, ENST00000581829, ENST00000582214, ENST00000582337, ENST00000584235, ENST00000949101, ENST00000949102

RefSeq mRNA: 4 — MANE Select: NM_017757 NM_001146189, NM_001146190, NM_001384475, NM_017757

CCDS: CCDS45885, CCDS54191, CCDS58634

Canonical transcript exons

ENST00000299687 — 9 exons

Exon	Start	End
ENSE00001104019	74641008	74641122
ENSE00001104029	74781428	74781502
ENSE00001179660	74920514	74920692
ENSE00001179669	74877197	74877363
ENSE00001179690	75063150	75065671
ENSE00002710413	74630967	74635706
ENSE00002723372	74597870	74597937
ENSE00003715156	74889918	74890038
ENSE00003716268	74881036	74881119

Expression profiles

Bgee: expression breadth ubiquitous, 265 present calls, max score 99.16.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.3593 / max 229.6578, expressed in 1622 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
170768	7.3593	1622

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	99.16	gold quality
oocyte	CL:0000023	97.35	gold quality
tibia	UBERON:0000979	91.25	gold quality
visceral pleura	UBERON:0002401	87.88	gold quality
parietal pleura	UBERON:0002400	87.62	gold quality
middle temporal gyrus	UBERON:0002771	87.57	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.95	gold quality
pleura	UBERON:0000977	86.46	gold quality
esophagus squamous epithelium	UBERON:0006920	86.19	gold quality
Brodmann (1909) area 23	UBERON:0013554	85.31	gold quality
germinal epithelium of ovary	UBERON:0001304	84.83	gold quality
calcaneal tendon	UBERON:0003701	84.34	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.55	gold quality
pigmented layer of retina	UBERON:0001782	82.87	gold quality
retina	UBERON:0000966	82.85	gold quality
sural nerve	UBERON:0015488	82.67	gold quality
endothelial cell	CL:0000115	81.89	gold quality
tendon	UBERON:0000043	80.34	gold quality
epithelium of esophagus	UBERON:0001976	80.32	gold quality
skin of hip	UBERON:0001554	79.81	gold quality
eye	UBERON:0000970	79.59	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	79.53	gold quality
amniotic fluid	UBERON:0000173	79.38	gold quality
adrenal tissue	UBERON:0018303	79.12	gold quality
palpebral conjunctiva	UBERON:0001812	78.51	gold quality
upper leg skin	UBERON:0004262	78.23	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	78.08	gold quality
tonsil	UBERON:0002372	78.04	gold quality
epithelium of nasopharynx	UBERON:0001951	78.01	gold quality
ventricular zone	UBERON:0003053	77.94	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	5.41

Regulation

Is transcription factor: yes

JASPAR motifs

Motif	Name	Family
MA2553.1	ZNF407	Factors with multiple dispersed zinc fingers

JASPAR matrix evidence (PMIDs): PMID:39605320

miRNA regulators (miRDB)

62 targeting ZNF407, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-7157-5P	99.66	69.33	1829
HSA-MIR-4261	99.59	70.30	3415

Functional genomics

ClinGen dosage: haploinsufficiency 0 (no evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map DepMap (CRISPR cell-line fitness): dependent in 83.7% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 3)

• Data indicate that mutations in the ZNF407 gene contribute to the pathogenesis of a group of intellectual disability (ID) patients with autism. (PMID:23195952)
• WDR5 shows a direct binding to the ZNF407 promoter. (PMID:28300833)
• Biallelic ZNF407 mutations in a neurodevelopmental disorder with ID, short stature and variable microcephaly, hypotonia, ocular anomalies and facial dysmorphism. (PMID:32737394)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	znf407	ENSDARG00000087536
mus_musculus	Zfp407	ENSMUSG00000048410
rattus_norvegicus	Zfp407	ENSRNOG00000043357

Paralogs (51): WIZ (ENSG00000011451), ZNF416 (ENSG00000083817), MYNN (ENSG00000085274), PRDM4 (ENSG00000110851), PRDM2 (ENSG00000116731), ZBTB17 (ENSG00000116809), ZNF644 (ENSG00000122482), GZF1 (ENSG00000125812), ZNF426 (ENSG00000130818), ZNF287 (ENSG00000141040), ZNF697 (ENSG00000143067), ZNF687 (ENSG00000143373), ZNF214 (ENSG00000149050), ZNF547 (ENSG00000152433), ZNF776 (ENSG00000152443), ZNF230 (ENSG00000159882), ZNF222 (ENSG00000159885), ZNF233 (ENSG00000159915), ZNF333 (ENSG00000160961), ZNF319 (ENSG00000166188), ZNF592 (ENSG00000166716), ZNF646 (ENSG00000167395), ZNF507 (ENSG00000168813), ZNF768 (ENSG00000169957), ZNF417 (ENSG00000173480), ZNF408 (ENSG00000175213), ZBTB41 (ENSG00000177888), ZNF223 (ENSG00000178386), ZNF852 (ENSG00000178917), ZNF784 (ENSG00000179922), ZNF572 (ENSG00000180938), ZNF707 (ENSG00000181135), ZNF746 (ENSG00000181220), ZNF467 (ENSG00000181444), ZNF530 (ENSG00000183647), ZNF17 (ENSG00000186272), ZNF527 (ENSG00000189164), ZKSCAN7 (ENSG00000196345), ZNF34 (ENSG00000196378), ZNF774 (ENSG00000196391)

Protein

Protein identifiers

Zinc finger protein 407 — Q9C0G0 (reviewed: Q9C0G0)

All UniProt accessions (3): A0A087WV78, A0A087WYH1, Q9C0G0

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Disease relevance. Short stature, impaired intellectual development, microcephaly, hypotonia, and ocular anomalies (SIMHA) [MIM:619557] An autosomal recessive syndrome characterized by short stature, impaired intellectual development, microcephaly, hypotonia, and ocular anomalies. The disease is caused by variants affecting the gene represented in this entry.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9C0G0-1	1	yes
Q9C0G0-2	2
Q9C0G0-3	3

RefSeq proteins (4): NP_001139661, NP_001139662, NP_001371404, NP_060227* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003604	Matrin/U1-like-C_Znf_C2H2	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050688	Zinc_finger/UBP_domain	Family

Pfam: PF00096

UniProt features (54 total): zinc finger region 22, sequence variant 10, sequence conflict 7, region of interest 6, splice variant 4, compositionally biased region 3, chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9C0G0-F1	46.31	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1262

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 156 (showing top): EFC_Q6, WANG_LMO4_TARGETS_DN, AML_Q6, WTGAAAT_UNKNOWN, GARY_CD5_TARGETS_DN, NKX22_01, chr18q22, GATA1_02, FOXJ2_02, TGGAAA_NFAT_Q4_01, WGTTNNNNNAAA_UNKNOWN, HAMAI_APOPTOSIS_VIA_TRAIL_UP, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, TEF_Q6, STAMBOLSKY_TARGETS_OF_MUTATED_TP53_UP

GO Biological Process (1): positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (4): DNA binding (GO:0003677), zinc ion binding (GO:0008270), nucleic acid binding (GO:0003676), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
nucleic acid binding	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

784 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF407	PTGR3	Q8N4Q0	577
ZNF407	SUSD4	Q5VX71	551
ZNF407	ADNP2	Q6IQ32	528
ZNF407	SLC66A2	Q8N2U9	505
ZNF407	FHAD1	B1AJZ9	499
ZNF407	SMIM21	Q3B7S5	480
ZNF407	RIBC1	Q8N443	475
ZNF407	ZNF385B	Q569K4	462
ZNF407	SEL1L3	Q68CR1	460
ZNF407	BCAS3	Q9H6U6	423
ZNF407	TSHZ3	Q63HK5	418
ZNF407	GNA12	Q03113	413
ZNF407	ZNF559	Q9BR84	409
ZNF407	TXNL4A	P83876	407
ZNF407	TSHZ1	Q6ZSZ6	400

IntAct

11 interactions, top by confidence:

A	B	Type	Score
NOTCH2	ZNF316	psi-mi:“MI:0914”(association)	0.530
ZNF407	ZBTB9	psi-mi:“MI:0915”(physical association)	0.370
ZNF407	ZSCAN1	psi-mi:“MI:0915”(physical association)	0.370
STAT6	ZNF407	psi-mi:“MI:0915”(physical association)	0.370
CAND1	GTPBP10	psi-mi:“MI:0914”(association)	0.350
CUL4A	HAX1	psi-mi:“MI:0914”(association)	0.350
FBLN5	ZNF320	psi-mi:“MI:0914”(association)	0.350
NOTCH2	ZNF320	psi-mi:“MI:0914”(association)	0.350
AFG2B	MMP24OS	psi-mi:“MI:0914”(association)	0.350
ZNF407	C1QTNF9	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (21): ZNF407 (Affinity Capture-MS), ZNF407 (Affinity Capture-RNA), ZNF407 (Two-hybrid), ZNF407 (Affinity Capture-MS), ZNF407 (Affinity Capture-MS), ZNF407 (Proximity Label-MS), STMN1 (Cross-Linking-MS (XL-MS)), ZNF407 (Cross-Linking-MS (XL-MS)), ZNF407 (Affinity Capture-MS), ZNF407 (Affinity Capture-RNA), ZNF407 (Proximity Label-MS), ZNF407 (Proximity Label-MS), ZNF407 (Proximity Label-MS), ZNF407 (Proximity Label-MS), ZNF407 (Proximity Label-MS)

ESM2 similar proteins: A0A5K7RLP0, A1YEX3, A7YWH3, B1WBU4, O15151, O35618, O43298, O88850, P24278, P97303, Q01954, Q0V8G8, Q15916, Q17RG1, Q562E2, Q5RC05, Q5RDQ6, Q5SXH7, Q5TC79, Q5VYS8, Q5W0Q7, Q5XIN1, Q6ZPY5, Q6ZSB9, Q6ZU67, Q7ZUW7, Q7ZYI3, Q8BLK9, Q8BSV3, Q8IW35, Q8K088, Q8N680, Q8N7W2, Q8TCN5, Q8VHI4, Q8WW38, Q90W33, Q96BR9, Q96S38, Q99ME3

Diamond homologs: O75362, Q9C0G0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

468 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	335
Likely benign	74
Benign	21

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1298357	NM_017757.3(ZNF407):c.5054C>G (p.Ser1685Trp)	Pathogenic

SpliceAI

4659 predictions. Top by Δscore:

Variant	Effect	Δscore
18:74781422:TTTTA:T	acceptor_loss	1.0000
18:74781423:TTTA:T	acceptor_loss	1.0000
18:74781424:TTA:T	acceptor_loss	1.0000
18:74781425:TAG:T	acceptor_loss	1.0000
18:74781426:A:AG	acceptor_gain	1.0000
18:74781426:AG:A	acceptor_gain	1.0000
18:74781426:AGG:A	acceptor_gain	1.0000
18:74781426:AGGGT:A	acceptor_loss	1.0000
18:74781427:G:A	acceptor_gain	1.0000
18:74781427:G:GA	acceptor_gain	1.0000
18:74781427:GGG:G	acceptor_gain	1.0000
18:74781427:GGGT:G	acceptor_gain	1.0000
18:74781427:GGGTT:G	acceptor_gain	1.0000
18:74781498:GAAAG:G	donor_gain	1.0000
18:74781503:G:GA	donor_loss	1.0000
18:74781504:T:G	donor_loss	1.0000
18:74898192:GCA:G	donor_gain	1.0000
18:74920505:ACTT:A	acceptor_gain	1.0000
18:74920506:C:G	acceptor_gain	1.0000
18:74920508:T:A	acceptor_gain	1.0000
18:74920508:TGGTA:T	acceptor_loss	1.0000
18:74920509:GGTAG:G	acceptor_loss	1.0000
18:74920510:GTA:G	acceptor_loss	1.0000
18:74920511:TAG:T	acceptor_loss	1.0000
18:74920512:A:AG	acceptor_gain	1.0000
18:74920512:AG:A	acceptor_gain	1.0000
18:74920513:G:GA	acceptor_gain	1.0000
18:74920513:GG:G	acceptor_gain	1.0000
18:74920513:GGT:G	acceptor_gain	1.0000
18:74920513:GGTC:G	acceptor_gain	1.0000

AlphaMissense

14937 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:74633138:T:C	C707R	1.000
18:74633147:T:C	C710R	1.000
18:74633225:T:A	C736S	1.000
18:74633225:T:C	C736R	1.000
18:74633226:G:A	C736Y	1.000
18:74633226:G:C	C736S	1.000
18:74633227:T:G	C736W	1.000
18:74633234:T:C	C739R	1.000
18:74633235:G:A	C739Y	1.000
18:74633236:T:G	C739W	1.000
18:74633573:T:C	C852R	1.000
18:74633575:T:G	C852W	1.000
18:74633582:T:C	C855R	1.000
18:74633583:G:A	C855Y	1.000
18:74633584:T:G	C855W	1.000
18:74633660:T:C	C881R	1.000
18:74633662:C:G	C881W	1.000
18:74633669:T:C	C884R	1.000
18:74634161:T:C	C1048R	1.000
18:74634163:C:G	C1048W	1.000
18:74635265:T:A	C1416S	1.000
18:74635265:T:C	C1416R	1.000
18:74635266:G:A	C1416Y	1.000
18:74635266:G:C	C1416S	1.000
18:74635267:T:G	C1416W	1.000
18:74635274:T:C	C1419R	1.000
18:74635275:G:A	C1419Y	1.000
18:74635276:T:G	C1419W	1.000
18:74635305:T:C	L1429P	1.000
18:74635355:T:C	C1446R	1.000

dbSNP variants (sampled 300 via entrez): RS1000000318 (18:74825482 A>G), RS1000004433 (18:74682922 G>A), RS1000006963 (18:74987408 C>T), RS1000010615 (18:74763359 A>G), RS1000022357 (18:74654595 C>A), RS1000050364 (18:75038686 C>T), RS1000053242 (18:74867781 C>G), RS1000064235 (18:75035575 T>C), RS1000076970 (18:74756704 G>A), RS1000097827 (18:74655979 A>C), RS1000100055 (18:74735825 T>G), RS1000106903 (18:74629202 A>G), RS1000116820 (18:74654901 T>G), RS1000124746 (18:74985213 T>G), RS1000142496 (18:74618159 T>C)

Disease associations

OMIM: gene MIM:615894 | disease phenotypes: MIM:619557, MIM:603438

GenCC curated gene-disease

Disease	Classification	Inheritance
short stature, impaired intellectual development, microcephaly, hypotonia, and ocular anomalies	Strong	Autosomal recessive
intellectual disability	Limited	Autosomal dominant
complex neurodevelopmental disorder	Limited	Autosomal recessive
neurodevelopmental disorder	Limited	Autosomal dominant

Mondo (5): short stature, impaired intellectual development, microcephaly, hypotonia, and ocular anomalies (MONDO:0859198), radioulnar synostosis-microcephaly-scoliosis syndrome (MONDO:0011320), intellectual disability (MONDO:0001071), complex neurodevelopmental disorder (MONDO:0100038), neurodevelopmental disorder (MONDO:0700092)

Orphanet (1): Radioulnar synostosis-microcephaly-scoliosis syndrome (Orphanet:3268)

HPO phenotypes

27 total (27 of 27 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000219	Thin upper lip vermilion
HP:0000286	Epicanthus
HP:0000365	Hearing impairment
HP:0000387	Absent earlobe
HP:0000411	Protruding ear
HP:0000486	Strabismus
HP:0000664	Synophrys
HP:0000750	Delayed speech and language development
HP:0001212	Prominent fingertip pads
HP:0001252	Hypotonia
HP:0001263	Global developmental delay
HP:0001488	Bilateral ptosis
HP:0001510	Growth delay
HP:0001845	Overlapping toe
HP:0002650	Scoliosis
HP:0002714	Downturned corners of mouth
HP:0002808	Kyphosis
HP:0003593	Infantile onset
HP:0004322	Short stature
HP:0004689	Short fourth metatarsal
HP:0005617	Bilateral camptodactyly
HP:0010864	Severe intellectual disability
HP:0011800	Midface retrusion
HP:0025335	Delayed ability to stand
HP:0030043	Hip subluxation
HP:0031936	Delayed ability to walk

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001553_8	Estradiol levels	4.000000e-06
GCST007327_108	Smoking status (ever vs never smokers)	2.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004697	estradiol measurement
EFO:0004318	smoking behavior

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, increases expression	5
Valproic Acid	affects expression, decreases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression, affects expression	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
arsenite	affects binding, decreases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
coumarin	decreases phosphorylation	1
beta-methylcholine	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
MT19c compound	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Caffeine	decreases phosphorylation	1
Cisplatin	decreases expression	1
Methapyrilene	increases methylation	1
Methotrexate	increases expression	1
Ozone	affects expression, increases abundance	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	increases expression	1
Copper Sulfate	increases expression	1

Clinical trials (associated diseases)

298 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study